Ken Griffin Ginkgo Bioworks Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$1.06 - $1.67 $70,601 - $111,230	-66,605 Reduced 22.56%	228,600 $265,000
Q4 2023 Feb 14, 2024	SELL	$1.26 - $1.79 $77,467 - $110,052	-61,482 Reduced 17.24%	295,205 $498,000
Q3 2023 Nov 14, 2023	SELL	$1.61 - $2.54 $92,019 - $145,173	-57,155 Reduced 13.81%	356,687 $645,000
Q2 2023 Aug 14, 2023	BUY	$1.14 - $1.95 $37,962 - $64,935	33,300 Added 8.75%	413,842 $769,000
Q1 2023 May 15, 2023	SELL	$1.2 - $2.19 $705,428 - $1.29 Million	-587,857 Reduced 60.7%	380,542 $506,000

Q4 2022 Feb 14, 2023	BUY	$1.63 - $3.52 $256,723 - $554,396	157,499 Added 19.42%	968,399 $1.64 Million
Q3 2022 Nov 14, 2022	BUY	$0.73 - $3.74 $247,105 - $1.27 Million	338,500 Added 71.66%	810,900 $2.53 Million

359

1.26B

845K

2.54M

Ticker DNA
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,287,779,968
Market Cap $489M
Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.